FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977373248> ?p ?o ?g. }

• W2977373248 endingPage "3" @default.
• W2977373248 startingPage "1" @default.
• W2977373248 abstract "Tel: 212-241-9955 Benign prostatic hyperplasia (BPH) is a common condition related to aging that can lead to a cluster of chronic symptoms collectively known as lower urinary tract symptoms (LUTS), including urinary frequency, urinary urgency, nocturia, hematuria, and decreased urinary stream. It is estimated that BPH affects 75% of men in the United States by age 70, with more than $1 billion US dollars a year spent in direct health care expenditures related to BPH, exclusive of outpatient medications [1]. Treatment options for BPH are outlined out by the American Urologic Association Clinical Guidelines and include watchful waiting, medical therapy, minimally invasive therapies (including transurethral ablations), or surgical therapies including open prostatectomy or transurethral resection of the prostate (TURP) [2]. Medical therapy is often considered the first-line option for symptomatic patients; however, a large subset of patients does not respond to or cannot tolerate pharmacotherapy, in part owing to a number of side effects including sexual dysfunction [3]. TURP has remained the ‘gold standard’ surgical treatment for BPH for over half a century, owing to its high success rate in reducing LUTS. Over the past two decades, the TURP procedure has undergone significant technical improvements, with morbidity rates reported to be <1% [4]. However, with a general shift towards minimally invasive treatment options, the number of TURPs performed has fallen in more recent years [5]. Manuscript Click here to download Manuscript SAPE final (1).docx Embolization of the prostatic arteries has been used for many years as a technique to control severe bladder and prostate hemorrhage as well as hematuria following TURP [6-9]. A case report by DeMeritt et al in 2000 described a patient with BPH and refractory hematuria treated by prostatic artery embolization, who subsequently had alleviation in his LUTS and reduction in the volume of his prostate [10]. This case report introduced the idea that BPH could intentionally be treated by selective arterial prostatic embolization (SAPE). In 2008, Carnevale et al used SAPE as the primary treatment in two patients with BPH [11]. After 6-month follow-up, MRI demonstrated a relative prostate reduction of 47.8% in the patient who had undergone bilateral SAPE and 27.8% in the patient who had undergone unilateral SAPE. Since this initial study, there has been an enthusiastic response in the literature regarding the future role of this technique, and the Society of Interventional Radiology has encouraged further research into this intervention [12]. A growing body of literature suggests that SAPE enables reduction in prostate volume with improvements in uroflometry parameters, quality of life, and sexual function [13]. The largest prospective non-randomized series published to date looked at 255 patients who underwent SAPE [14]. The authors describe technical success in 250 of the patients (98%), with a clinical success rate of 82% at one month decreasing to 72% at 3 years. In the only RCT to date assessing SAPE, 57 patients were assigned to prostatic artery embolization and 57 were assigned to TURP for the treatment of BPH [15]. The authors demonstrated that all parameters: including improvement of the International Prostate Symptom Score (IPSS), quality of life (QOL), peak urinary flow, and post void residual(PVR) urine volume were improved by both treatment modalities and there was no difference at two years between the treatment arms. The paper does state there was a higher complication rate for PAE, if one controls for acute urinary retention post operatively, there would be similar complication rates for both groups. The technique for SAPE involves unilateral access of the femoral artery and subsequent catheterization of the anterior division of the internal iliac artery. Digital subtraction angiography is used to confirm arterial anatomy and allow for superselective catheterization of the prostatic artery. A number of different embolic materials have been used, including polyvinyl alcohol particles, trisacryl gelatin microspheres, and Embozene Selective Arterial Prostatic Embolization (SAPE) for the Treatment of Lower Urinary Tract Symptoms in the Setting of Benign Prostatic Hyperplasia: A Brief Review" @default.
• W2977373248 created "2019-10-10" @default.
• W2977373248 creator A5048266835 @default.
• W2977373248 creator A5055473847 @default.
• W2977373248 creator A5066835322 @default.
• W2977373248 creator A5067140264 @default.
• W2977373248 creator A5081237008 @default.
• W2977373248 date "2016-01-01" @default.
• W2977373248 modified "2023-09-26" @default.
• W2977373248 title "Selective Arterial Prostatic Embolization (SAPE) for the Treatment of Lower Urinary Tract Symptoms in the Setting of Benign Prostatic Hyperplasia: A Brief Review" @default.
• W2977373248 cites W1979677964 @default.
• W2977373248 cites W1982248967 @default.
• W2977373248 cites W1992683171 @default.
• W2977373248 cites W2005687876 @default.
• W2977373248 cites W2008010444 @default.
• W2977373248 cites W2023089246 @default.
• W2977373248 cites W2025211994 @default.
• W2977373248 cites W2035136023 @default.
• W2977373248 cites W2066452347 @default.
• W2977373248 cites W2073281150 @default.
• W2977373248 cites W2085582807 @default.
• W2977373248 cites W2089765000 @default.
• W2977373248 cites W2095572883 @default.
• W2977373248 cites W2105669626 @default.
• W2977373248 cites W2137410202 @default.
• W2977373248 cites W2152788789 @default.
• W2977373248 cites W2158304281 @default.
• W2977373248 cites W2199520567 @default.
• W2977373248 hasPublicationYear "2016" @default.
• W2977373248 type Work @default.
• W2977373248 sameAs 2977373248 @default.
• W2977373248 citedByCount "0" @default.
• W2977373248 crossrefType "journal-article" @default.
• W2977373248 hasAuthorship W2977373248A5048266835 @default.
• W2977373248 hasAuthorship W2977373248A5055473847 @default.
• W2977373248 hasAuthorship W2977373248A5066835322 @default.
• W2977373248 hasAuthorship W2977373248A5067140264 @default.
• W2977373248 hasAuthorship W2977373248A5081237008 @default.
• W2977373248 hasConcept C121608353 @default.
• W2977373248 hasConcept C126322002 @default.
• W2977373248 hasConcept C126894567 @default.
• W2977373248 hasConcept C141071460 @default.
• W2977373248 hasConcept C2776141087 @default.
• W2977373248 hasConcept C2776235491 @default.
• W2977373248 hasConcept C2776547966 @default.
• W2977373248 hasConcept C2777333188 @default.
• W2977373248 hasConcept C2777562237 @default.
• W2977373248 hasConcept C2779091618 @default.
• W2977373248 hasConcept C2779466945 @default.
• W2977373248 hasConcept C2779478474 @default.
• W2977373248 hasConcept C2779929075 @default.
• W2977373248 hasConcept C2780070792 @default.
• W2977373248 hasConcept C2780192828 @default.
• W2977373248 hasConcept C2780768273 @default.
• W2977373248 hasConcept C71924100 @default.
• W2977373248 hasConcept C77411442 @default.
• W2977373248 hasConceptScore W2977373248C121608353 @default.
• W2977373248 hasConceptScore W2977373248C126322002 @default.
• W2977373248 hasConceptScore W2977373248C126894567 @default.
• W2977373248 hasConceptScore W2977373248C141071460 @default.
• W2977373248 hasConceptScore W2977373248C2776141087 @default.
• W2977373248 hasConceptScore W2977373248C2776235491 @default.
• W2977373248 hasConceptScore W2977373248C2776547966 @default.
• W2977373248 hasConceptScore W2977373248C2777333188 @default.
• W2977373248 hasConceptScore W2977373248C2777562237 @default.
• W2977373248 hasConceptScore W2977373248C2779091618 @default.
• W2977373248 hasConceptScore W2977373248C2779466945 @default.
• W2977373248 hasConceptScore W2977373248C2779478474 @default.
• W2977373248 hasConceptScore W2977373248C2779929075 @default.
• W2977373248 hasConceptScore W2977373248C2780070792 @default.
• W2977373248 hasConceptScore W2977373248C2780192828 @default.
• W2977373248 hasConceptScore W2977373248C2780768273 @default.
• W2977373248 hasConceptScore W2977373248C71924100 @default.
• W2977373248 hasConceptScore W2977373248C77411442 @default.
• W2977373248 hasIssue "2" @default.
• W2977373248 hasLocation W29773732481 @default.
• W2977373248 hasOpenAccess W2977373248 @default.
• W2977373248 hasPrimaryLocation W29773732481 @default.
• W2977373248 hasRelatedWork W1408604542 @default.
• W2977373248 hasRelatedWork W2015630668 @default.
• W2977373248 hasRelatedWork W2050440257 @default.
• W2977373248 hasRelatedWork W2086561958 @default.
• W2977373248 hasRelatedWork W223787745 @default.
• W2977373248 hasRelatedWork W2264638165 @default.
• W2977373248 hasRelatedWork W2412271542 @default.
• W2977373248 hasRelatedWork W2413043765 @default.
• W2977373248 hasRelatedWork W2789842800 @default.
• W2977373248 hasRelatedWork W2790348249 @default.
• W2977373248 hasRelatedWork W2790964937 @default.
• W2977373248 hasRelatedWork W2793287811 @default.
• W2977373248 hasRelatedWork W2806526587 @default.
• W2977373248 hasRelatedWork W2906933632 @default.
• W2977373248 hasRelatedWork W2913497370 @default.
• W2977373248 hasRelatedWork W2941146473 @default.
• W2977373248 hasRelatedWork W3017495686 @default.
• W2977373248 hasRelatedWork W3106602647 @default.
• W2977373248 hasRelatedWork W3209886123 @default.
• W2977373248 hasRelatedWork W427420938 @default.

• next